Drug Profile
Research programme: immuno-oncology and autoimmune therapeutics - Tizona Therapeutics
Latest Information Update: 11 Mar 2022
Price :
$50
*
At a glance
- Originator Tizona Therapeutics
- Class Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Interleukin receptor agonists; Interleukin receptor antagonists; Regulatory T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in USA
- 18 Apr 2018 Tizona Therapeutics signs a second contract development and manufacturing agreement with ProBioGen